JP2024518270A5 - - Google Patents

Info

Publication number
JP2024518270A5
JP2024518270A5 JP2023562616A JP2023562616A JP2024518270A5 JP 2024518270 A5 JP2024518270 A5 JP 2024518270A5 JP 2023562616 A JP2023562616 A JP 2023562616A JP 2023562616 A JP2023562616 A JP 2023562616A JP 2024518270 A5 JP2024518270 A5 JP 2024518270A5
Authority
JP
Japan
Prior art keywords
vitamin
composition according
composition
erythritol
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/061949 external-priority patent/WO2022233922A1/en
Publication of JP2024518270A publication Critical patent/JP2024518270A/ja
Publication of JP2024518270A5 publication Critical patent/JP2024518270A5/ja
Pending legal-status Critical Current

Links

JP2023562616A 2021-05-06 2022-05-04 イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 Pending JP2024518270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185097P 2021-05-06 2021-05-06
US63/185,097 2021-05-06
PCT/EP2022/061949 WO2022233922A1 (en) 2021-05-06 2022-05-04 Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii

Publications (2)

Publication Number Publication Date
JP2024518270A JP2024518270A (ja) 2024-05-01
JP2024518270A5 true JP2024518270A5 (enExample) 2025-03-05

Family

ID=81941092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562616A Pending JP2024518270A (ja) 2021-05-06 2022-05-04 イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法

Country Status (5)

Country Link
US (1) US20240226030A1 (enExample)
EP (1) EP4333644A1 (enExample)
JP (1) JP2024518270A (enExample)
CN (1) CN117119907A (enExample)
WO (1) WO2022233922A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202316101D0 (en) * 2023-10-20 2023-12-06 Tate & Lyle Solutions Usa Llc Compositions and uses
WO2025083419A1 (en) * 2023-10-20 2025-04-24 Tate & Lyle Solutions Usa Llc Allulose or erythritol for use in improving gut microbiota population and medical treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544781A1 (en) * 2003-11-04 2005-05-12 Meiji Dairies Corporation Plant-derived .beta.3-adrenergic receptor agonist substances and uses thereof
JP2007051132A (ja) * 2005-07-19 2007-03-01 Hokkaido Sugar Co Ltd イノシトールを成分とする食用組成物または医薬組成物
CN101156867A (zh) * 2007-10-19 2008-04-09 北京协和建昊医药技术开发有限责任公司 茶多酚膜剂及其制备方法
WO2010083227A1 (en) * 2009-01-14 2010-07-22 Nutrafood Nutrients, Inc. Consumable dissolving film comprising active ingredients derived from bacteria and fungi
US20110189318A1 (en) * 2010-01-29 2011-08-04 Misato Sugahara Methods for enhancing the expression of intracellular redox-associated factors
WO2011122879A2 (ko) * 2010-03-31 2011-10-06 (주)아모레퍼시픽 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물
JP2012065607A (ja) * 2010-09-24 2012-04-05 Hirotaro Matsui サプリメント
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
US20150209383A1 (en) * 2011-11-04 2015-07-30 General Mills, Inc. Methods and compositions for modulating gastrointestinal bacteria to promote health
EP2664606B1 (en) * 2012-04-25 2016-09-14 Ueno Fine Chemicals Industry, Ltd. An inhibitor of the production of advanced glycation end products
MX2015011700A (es) * 2013-03-05 2016-07-20 Univ Groningen Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
MX374421B (es) * 2014-08-08 2025-03-06 Soc Des Produits Nestle S A Star Mioinositol y uno o más probióticos y sus usos.
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
CN107802576A (zh) * 2016-09-07 2018-03-16 酷美生物科技（上海）有限公司 一种天然动植物细胞补充剂及其制备方法
CN107252112A (zh) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 一种含egcg的片剂
US11484569B2 (en) * 2017-07-13 2022-11-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria
US11898184B2 (en) * 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
CN108309960A (zh) * 2018-04-24 2018-07-24 温州医科大学附属第医院 肌醇在制备抗炎药物中的应用
FR3099053B1 (fr) * 2019-07-24 2023-01-20 Inst Nat De La Rech Agronomique Inra Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale
CN110973630A (zh) * 2019-12-20 2020-04-10 美益添生物医药(武汉)有限公司 一种抗肠道衰老的组合物及其应用
CN112402459B (zh) * 2020-10-27 2023-01-31 江南大学 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用
CN112625964B (zh) * 2020-12-29 2022-08-02 江南大学 一株鼠李糖乳杆菌在预防和缓解溃疡性结肠炎中的应用

Similar Documents

Publication Publication Date Title
Zakay-Rones et al. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections
Maggini et al. A combination of high-dose vitamin C plus zinc for the common cold
US9662359B2 (en) Compositions and methods for treating depression
RU2606768C1 (ru) Очищенный экстракт, выделенный из pseudolysimachion rotundum var subintegrum, с высоким содержанием активного ингредиента, его получение и композиция, содержащая указанный экстракт в качестве активного ингредиента, для предотвращения или лечения воспаления, аллергии и астмы
US10471084B2 (en) Composition and method for treating acute respiratory tract infections
US9907809B2 (en) Antiviral supplement formulations
Paudel et al. Nutraceuticals and COVID‐19: A mechanistic approach toward attenuating the disease complications
JP2017506651A (ja) 脂肪肝の低減または予防のための組成物および方法
JP2014198723A5 (enExample)
TW202015664A (zh) 用於治療肝疾病及失調之組合物及方法
Clemente-Suárez et al. Basis of preventive and non-pharmacological interventions in asthma
TR201902517T4 (tr) 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi.
WO2016159593A9 (ko) 락토코커스 중앙젠시스를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
JP2023536841A (ja) Ｃｏｖｉｄ－１９及び関連する病態の治療及び予防のためのノビレチン組成物ならびに方法
JP2011073973A (ja) 更年期のための疲労改善組成物
JP2016528279A (ja) モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物
US20240277750A1 (en) Compositions and methods for treating depression
JP6708376B2 (ja) ＩＦＮ−γ及び／又はＩＬ−１７の産生抑制剤、並びにＴｈ１細胞及び／又はＴｈ１７細胞の分化抑制剤
US9770477B2 (en) Natural antioxidant anti-influenza composition
JP4359046B2 (ja) 抗ストレス剤
JP2017119641A (ja) Ｎａｓｈの可能性の試験方法並びに経口組成物
JP4210190B2 (ja) ストレス緩和剤
Mukhopadhyay et al. Beneficial Effect of Nutraceuticals on Respiratory Diseases
JP2017523171A (ja) アレルギー性疾患、炎症性疾患、喘息又は慢性閉塞性肺疾患の予防又は治療のための、十分な量の有効成分を含有する、シュードリシマキオン・ロツンダム変種スブインテグルムから単離された新規の化合物、その化合物を含む組成物及びその使用
WO2012147327A1 (ja) 抗新型インフルエンザウイルス剤